Ronald L. Paquette, MD, discusses characteristics of myelodysplastic syndrome and how they may impact a patient’s success in undergoing stem cell transplant.
Ronald L. Paquette, MD, clinical director, Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, discusses
characteristics of myelodysplastic syndrome and how they may impact a patient’s success in undergoing stem cell transplant.
According to Paquette, each patient has a different profile in terms of the histopathologic, cytologic, and molecular features. Moreover, clinical features like a patient’s fitness for therapy, age, and the number and type of comorbidities all impact a physician’s decision-making.
Choosing to transplant often comes down to identifying which patients with MDS have a high enough risk-level to be selected for transplant.
0:07 | Well, the first thing that is important is patient selection. So, I always tell my patients that no 2 patients are alike because of the histopathological features, the cytogenetic features, the molecular features are often dissimilar between two patients that might otherwise be comparable. And you have clinical features like how fit is the patient, how old is the patient, and what are their comorbidities?
0:37 | And so, patient selection for transplant is very important and identifying the patients for whom the risk of the disease is high enough that a curative option like transplant is appropriate and warranted. And then determining which of that population of patients would be able to be successful with a transplant in terms of tolerating the conditioning regimen and the risks of graft-versus-host disease prophylaxis.
1:08 | So that's it, the selection process is convoluted and oftentimes less than clear cut one but many variables have to be taken into account in order to determine who might be a suitable candidate for transplant.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
FDA Approves Remestemcel-L in Pediatric Patients With Acute GVHD
December 18th 2024Following a complete response letter and biologics license application resubmission, the FDA has approved remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host disease.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More